Alpha Tau's Alpha DaRT Could Be a Game-Changer for Solid Tumors—Here's What's Coming

Alpha Tau Medical (DRTS) just filed for Japanese regulatory clearance on Alpha DaRT for recurrent head & neck cancer, with approval expected by year-end 2025. If greenlit, this becomes the first major regulatory win for the company’s localized alpha radiation platform.

The Tech: Why This Matters

Alpha DaRT is fundamentally different from traditional chemo. Instead of systemic toxicity, it delivers concentrated alpha radiation directly into tumors while preserving nearby healthy tissue. Think of it as precision strikes vs. carpet bombing—less collateral damage, potentially fewer side effects.

Pipeline Deep Dive

The company isn’t betting everything on head & neck. Here’s their parallel push:

• Pancreatic cancer: U.S. pilot study running; recruitment wraps Q1 2026. This matters because ~80% of pancreatic patients are inoperable at diagnosis—massive unmet need.
• Glioblastoma: First patient expected before year-end 2025 in the U.S. trial.
• Brain metastases, liver mets, lung cancer, prostate, vulvar cancer: Earlier feasibility studies across Israel, Canada, U.K., and U.S.
• Combo therapy: Testing Alpha DaRT + pembrolizumab for locally advanced/metastatic head & neck cancer in Israel.

The Reality Check

Alpha Tau burned $30.5M in the first nine months of 2025 (vs. $23.6M in 2024)—losses accelerating as clinical trials scale up. Cash runway: $75.9M at Q3, enough through 2027.

Stock performance? DRTS has ranged $2.20–$4.69 over 12 months; currently sitting at $3.47 after a 5.45% dip.

What’s Next

Japan approval would validate the platform. U.S. ReSTART trial completion (Q1 2026) and pancreatic pilot readout could be the next catalysts. If Alpha DaRT proves efficacy across multiple solid tumor types, it reshapes the oncology toolkit—but the burn rate means execution matters more than pipeline breadth right now.